Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer
Phase II Clinical Study: A Randomized, Open, and Dose Ranging Study to Evaluate the Efficacy and Safety of DLBS1425 in Subjects With Metastatic / Advanced Breast Cancer
Sponsor: Dexa Medica Group
Terminated
The study was terminated due to difficulty of find eligible subjects
Other terminated trials from Dexa Medica Group
- Acute Ischemic Stroke · Phase PHASE2/PHASE3 · Apr 2023
- Gastroesophageal Reflux Disease (GERD) · Phase PHASE3 · Sep 2020
- Non-Bleeding Peptic Ulcers · Phase PHASE3 · Mar 2019
- Diabetes · Phase PHASE2/PHASE3 · Jul 2018
- Acute Ischemic Stroke · Phase PHASE3 · Apr 2017
More terminations from Dexa Medica Group
This PHASE2 trial investigates Breast Cancer and is currently terminated or withdrawn. Dexa Medica Group leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Aug 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dexa Medica Group
For direct contact, visit the study record on ClinicalTrials.gov .